





UV1: Encouraging Safety & Efficacy in Melanoma

Supports our Broad Phase II
Combination Program in Solid Tumors

ASCO Update, May 2021



Disclaimer

NOT FOR DISTRIBUTION IN THE UNITED STATES, EXCEPT PURSUANT TO APPLICABLE EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT OF 1933.

This presentation has been prepared by Ultimovacs ASA (“Ultimovacs” or the “Company”) solely for use at the presentation to investors held in connection with the contemplated initial public offering of shares of the Company conducted towards Norwegian investors and international institutional investors and to investors in such jurisdictions as permitted or catered for by exemption rules under applicable securities laws (the “Transaction”). This presentation is strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other person.

This presentation is based on the economic, regulatory, market and other conditions in effect on the date hereof and, may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Ultimovacs’ current expectations and assumptions as to future events and circumstances that may not prove accurate. None of the Company, nor ABG Sundal Collier ASA or DNB Markets, a part of DNB Bank ASA (together the “Managers”) or any of their parent or subsidiary undertakings or any such person’s officers or employees provide any assurance as to the correctness of such forward-looking information and statements. It should be understood that subsequent developments may affect the information contained in this document, which neither Ultimovacs, nor its advisors, are under an obligation to update, revise or affirm. Important factors that could cause actual results to differ

materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for the Company’s businesses, changes in governmental regulations, interest rates and fluctuations in currency exchange rates.

This presentation is for information purposes only and does not constitute an offer to sell common shares of the Company or a recommendation in relation to the shares of the Company. This presentation is not a prospectus, disclosure document or offering document and does not purport to be complete. Nothing in this presentation should be interpreted as a term or condition of the Transaction. Potential investors in the Transaction will be bound by the final terms as set out in the relevant subscription documentation.

AN INVESTMENT IN THE COMPANY INVOLVES SIGNIFICANT RISK AND, SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE EXPRESSED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION.

No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including but not limited to projections, estimates, targets and opinions, contained herein, and no liability or responsibility whatsoever is accepted as to the accuracy or completeness of this presentation or for any errors, omissions or misstatements contained herein, and, accordingly, none of the Company nor the Managers nor any of their parent or subsidiary

undertakings or any such person’s officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. This presentation does not purport to contain all of the information that may be required to evaluate the Company and its shares and should not be relied on in connection with an investment in the Company.

The contents of this presentation are not to be construed as legal, business, investment or tax advice. Each recipient should consult with its own legal, business, investment or tax adviser as to legal, business, investment or tax advice. By attending or receiving this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company’s business and the securities issued by the Company.

This presentation has not been reviewed or approved by any regulatory authority or stock exchange. The distribution of this presentation and/or any prospectus or other documentation into jurisdictions other than Norway may be restricted by law. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire any securities offered by any person in any jurisdiction in which such an offer or solicitation is unlawful. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Persons into whose possession this presentation comes should inform themselves about and observe any such

restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This presentation is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Australia or Japan. This presentation does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U. S. Securities Act of 1933 (the “Securities Act”). The securities mentioned herein may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.


This Presentation is subject to Norwegian law and any dispute arising in respect of this presentation is subject to the exclusive jurisdiction of the Norwegian courts with Oslo district court as the legal venue.

ASCO UV1 Efficacy and Safety Data Supports Broad Phase II Program

- UV1, a novel immune-stimulatory vaccine, is being evaluated in a Phase I/II Trial in Advanced Malignant Melanoma patients in combination with the standard of care pembrolizumab
- Interim data from this trial are being presented at the ASCO conference, June 4-8th
- Key results from 1st study cohort (20 patients) in 21-month follow up show that UV1 when used in combination with pembrolizumab:
 - is safe and well tolerated
 - helps shrink melanoma tumors more than pembrolizumab monotherapy alone
 - helps patients with melanoma live longer versus pembrolizumab monotherapy alone
- Supports our broad Phase II combination program with checkpoint inhibitors
- Broad Combination Potential for UV1 in multiple cancer types
 - Clinical data opens the door to future collaborations in combination therapy
 - UV1 is uniquely positioned in Phase II trials with 4 out of the top 5 CPI's, and enrolling >500 patients


Telomerase (hTERT) is an Ideal Target Antigen in Cancer Immunotherapy

Telomerase preserves telomers in cancer cells



Normal cell = normal cell death and replacement

Cancer cell = Unlimited, uncontrolled cell division




Telomerase is a **universal target**:
85-90% of cancer cells express hTERT

Telomerase is an **essential target**:
Tumor cells are dependent on expressing hTERT

- Most normal cells are telomerase-negative
- Telomerase's function and relevance for tumor is well known and documented
- Telomerase is present in cancer stem cells and therefore also in all tumor cells
- Telomerase is essential for unlimited growth and immortality
- Telomerase is also essential for tumor spread

UV1 Activates hTERT Specific CD4-helper T Lymphocytes



UV1 Works Synergistically with Check Point Inhibitors (CPIs)


UV1 activates, educates and expands the patient's immune cells, killing the cancer cells



CPIs, e.g., pembrolizumab and nivolumab, block important cancer cells' defense mechanisms against the patient's immune cells.

UV1/pembrolizumab Phase I Design in First Line Advanced Malignant Melanoma

- Ultimovacs sponsored study running in the U.S.
- Enrollment of all 30 patients completed in Q3 2020
- ASCO 2021 update: 21-month follow-up of cohort 1



Demographics: Comparable to Pembrolizumab Registrational Trial

Total of 20 patients without earlier treatment for advanced malignant melanoma were included in cohort 1

Male / Female	13 / 7
Median Age (Range)	70 (31-82)
ECOG 0 / 1	15 / 5
Stage IIIb, IIIc, IV	2 / 8 / 10
Elevated LDH	5
UV1 / GM-CSF Doses (# of Patients)	8 doses (17)
	7 doses (2)
	6 doses (1)

ECOG: performance status scale developed by the Eastern Cooperative Oncology Group (ECOG)

LDH: lactate dehydrogenase. The lactate dehydrogenase (LDH) test, looks for signs of damage to the body's tissues

GM-CSF: adjuvant used in vaccines


UV1 is Safe and Well Tolerated

- Safety profile manageable, and as expected for a PD1 antibody (e.g., pembrolizumab) except injection site reactions which are related to the vaccine
- The major adverse events reported were grade 1 (48%) and grade 2 (41%)*
- Main adverse events were fatigue (8%), injection site reactions (5%), diarrhea (4%) and pyrexia (3%)*

Key Efficacy Results

- All patients have been observed a minimum of 18 months
 - Median observation time is 21 months as of May 2021
 - Responses as measured:
 - complete response (CR) 6/20
 - partial response (PR) 6/20
 - stable disease (SD) 1/20
 - progressive disease (PD) 7/20
- Objective Response Rate (ORR) 60%**
- Median Progression Free Survival (mPFS): 18.9 months
 - Overall Survival (OS): 80%
 - Median Overall Survival (mOS): not yet reached*

UV1 added to pembrolizumab clearly improves Response Rate compared with pembrolizumab alone



¹ Data from KEYNOTE-006 (Robert C, 2019). KEYNOTE-006 is the pivotal study referred to in the Keytruda (pembrolizumab) package inserts. Data from Robert C (2019) is a post-hoc non-planned analysis UV1/pembrolizumab phase I/II trial measured by iRECIST KEYNOTE-006 was measured by RECIST 1.1.

UV1 added to pembrolizumab helps patients with melanoma live longer compared with pembrolizumab alone


Median Progression Free Survival

Topline readout of Cohort 1 from Phase 1 trial in malignant melanoma vs historic pembrolizumab data



Overall Survival at 18 months

Topline readout of Cohort 1 from Phase 1 trial in malignant melanoma vs historic pembrolizumab data




¹ From Keynote 006 (Robert C, 2019) UV1/pembrolizumab phase I/II trial measured by iRECIST KEYNOTE-006 was measured by RECIST 1.1.

² Visual reading from KEYNOTE-006 Kaplan Meyer graph at 18 months

Next Steps for UV1 in Advanced Malignant Melanoma

- **ASCO presentation and poster, June 4-8**
 - Cohort 1: 21 months follow up
- **Phase I combination trial with pembrolizumab**
 - Cohort 1: 2 year follow up in Q4 2021
 - Cohort 2: 1 year follow up in Q4 2021
- **INITIUM Phase II combination trial with nivolumab and ipilimumab in advanced malignant melanoma**
 - Enrollment ongoing since June 2020
 - 154 patients in 40 sites in 4 countries (US, UK, Belgium and Norway)



Data Supports our Broad Phase II Pipeline in >500 Patients

	Indication	Clinical trial information	Pre-clinical	Phase I	Phase II	Phase III	Participating entities
UV1	First line metastatic malignant melanoma	With pembrolizumab 30 patients		●			
	First line metastatic malignant melanoma	With ipilimumab & nivolumab 154 patients			INITIUM ●		
	Second line mesothelioma	With ipilimumab & nivolumab 118 patients			NIPU ●		 
	Second line ovarian cancer	With durvalumab & olaparib 184 patients			DOVACC ●		  AstraZeneca 
	First line head and neck cancer	With pembrolizumab 75 patients			FOCUS ●		 Martin-Luther University Halle network

Note: UV1 Phase II development is supported by good safety profile and signals of clinical efficacy observed in three Phase 1 trials with 5 year follow up in 52 patients in prostate, NSCLC and malignant melanoma

The Commercial Potential and Key Market Players



Immuno-oncology is the fastest growing pharmaceutical segment

IMMUNO-ONCOLOGY IN BRIEF

Immuno-Oncology is designed to help the body's own immune system fight cancer by either activating the immune system against cancer cells or by suppressing factors that limit the immune system's ability to kill cancer cells such as checkpoint inhibitors

FDA APPROVED CHECKPOINT INHIBITORS*



TOTAL MARKET SIZE 2019

\$24bn

TOTAL MARKET SIZE 2026e


\$67bn

CAGR 2019-2026e

16%

UV1 Uniquely Positioned in Phase II trials with 4 out of the top 5 CPI's*

INITIUM	ipilimumab/nivolumab - CTL4/PD1	Malignant melanoma
NIPU	ipilimumab/nivolumab - CTL4/PD1	Mesothelioma
DOVACC	durvalumab/Olaparib** - PD-L1/PARPi	Ovarian Cancer
FOCUS	pembrolizumab - PD1	Head & Neck cancer



- ### Marketed CPI's
1. Pembrolizumab (Keytruda®)
 2. Nivolumab (Opdivo®)
 3. Atezolizumab (Tecentriq®)
 4. Ipilimumab (Yervoy®)
 5. Durvalumab (Imfinzi®)
 6. Cemiplimab (Libtayo®)
 7. Sintilimab (Tyvyt®)
 8. Avelumab (Bavencio®)

Broad Combination Potential for UV1 in multiple cancer types¹

Clinical data opens the door to future collaborations in combination therapy



	Keytruda®	Opdivo®	Imfinzi®	Tecentriq®	Bavencio®	Yervoy®	Lynparza®	UV1
(As per January 2021)	pembrolizumab	nivolumab	durvalumab	atezolizumab	avelumab	ipilimumab	olaparib ²	
Malignant melanoma								
NSCLC								
HNSCC								
Mesothelioma						Nivo + Ipi		
Ovarian								
Prostate								
SCLC								
Renal						Nivo + Ipi		
Urothelial								
MSI-high								
Gastric								
Cervical								
Hepatocellular								
Merkel cell								
Hodgkins								
Large B-cell								
Breast								
Pancreatic								
Esophageal								
Endometrial								
Cutaneous squamous cell								
Colon								



CPI approved indication



UV1 clinical trials



UV1 opportunity

¹ Indications per Q1 2021
² PARP inhibitor

Exciting Times Ahead

- Excellent safety and efficacy data being presented at ASCO on the melanoma study in combination with pembrolizumab
- New data to be presented in Q4 2021, including first results from 2nd cohort
- Ambitious and broad Phase II plan progressing
 - Patient enrollment to continue in the INITIUM and NIPU studies
 - Patient enrollment in the DOVACC and FOCUS studies to start soon
- We keep regular discussions with Pharma and Biotech companies while preparing for future program collaboration

- **4 June 2021 at 15.00 CET: ASCO Release of Poster presentation**



Activating the immune system to fight cancer

Carlos de Sousa, CEO

carlos.desousa@ultimovacs.com

+47 908 92507

Hans Vassgård Eid, CFO

hans.eid@ultimovacs.com

+47 482 48632

Ton Berkien, CBO

ton.berkien@ultimovacs.com

+46 707 914954

Jens Bjørheim, CMO

jens.bjorheim@ultimovacs.com

+47 475 03831

www.ultimovacs.com